Irritable bowel syndrome (IBS) is a chronic, functional, non-inflammatory, relapsing gastrointestinal problem, characterized by abdominal pain or discomfort, bloating and changes in bowel habits. The goal of this activity is to update pharmacists on the management of IBS and how they can play a role in co-managing this condition.
Bloating is a common problem that is usually functional, but investigations to exclude organic disease may be needed depending on patient age, symptoms and signs. Treatment should be individualized and usually begins with dietary changes, followed by a short-term trial of medications if needed.
In this series, we present authoritative advice on the investigation of a common clinical problem, especially commissioned for family doctors and written by members of the Royal Australasian College of Physicians.
Saccharomyces boulardii has favourable safety and efficacy in the treatment of children aged 3 months to 5 years with acute rotavirus diarrhoea, based on a double-blind, randomised controlled trial from a developing country.
Celecoxib is preferred over naproxen when added to proton-pump inhibitor (PPI) for preventing recurrent upper gastrointestinal (GI) bleeding in patients at high risk of both GI and cardiovascular (CV) events, who require concomitant aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs), according to the CONCERN* study.